Mavatrep

Mavatrep
Clinical data
Other names	JNJ-39439335
Identifiers
	IUPAC name 2-[2-[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-3H-benzimidazol-5-yl]phenyl]propan-2-ol;
CAS Number	956274-94-5;
PubChem CID	17751090;
DrugBank	DB12875;
ChemSpider	29271895;
UNII	F197218T99;
ChEMBL	ChEMBL2364618;
CompTox Dashboard (EPA)	DTXSID90241905 ;
Chemical and physical data
Formula	C25H21F3N2O
Molar mass	422.451 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)/C=C/C4=CC=C(C=C4)C(F)(F)F)O;
	InChI InChI=1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+; Key:ORDHXXHTBUZRCN-NTEUORMPSA-N;

Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist.[1] It is an investigational analgesic that may be a potential treatment for analgesia and/or inflammation.

Phase I trials have been completed in healthy Japanese and Caucasian volunteers.[1][2]

Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.[2]

Pharmacokinetics

When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days.[2] It has a relatively long half life between 68–101 hours in Japanese subjects and between 82–130 hours in Caucasian subjects.[2]

Mavatrep is largely eliminated nonrenally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.[2]

gollark: Kiki: speak for yourself!

gollark: I put that adaptation of the poem up on the hub.

gollark: Exactly.

gollark: And "against the 6-year-old T&C".

gollark: But under moderator logic, that's "harrasment".

References

Manitpisitkul P, Shalayda K, Russell L, Sanga P, Williams Y, Solanki B, et al. (September 2018). "Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies". Clinical Pharmacology in Drug Development. 7 (7): 699–711. doi:10.1002/cpdd.412. PMID 29125700. S2CID 32666782.
Manitpisitkul P, Shalayda K, Russell L, Sanga P, Solanki B, Caruso J, et al. (September 2018). "Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study". Clinical Pharmacology in Drug Development. 7 (7): 712–726. doi:10.1002/cpdd.413. PMID 29125703. S2CID 11755963.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[:0-1] Manitpisitkul P, Shalayda K, Russell L, Sanga P, Williams Y, Solanki B, et al. (September 2018). "Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies". Clinical Pharmacology in Drug Development. 7 (7): 699–711. doi:10.1002/cpdd.412. PMID 29125700. S2CID 32666782.

[:1-2] Manitpisitkul P, Shalayda K, Russell L, Sanga P, Solanki B, Caruso J, et al. (September 2018). "Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study". Clinical Pharmacology in Drug Development. 7 (7): 712–726. doi:10.1002/cpdd.413. PMID 29125703. S2CID 11755963.